An up-to-date overview of bone metastases management: A systematic review
DOI:
https://doi.org/10.58814/01208845.543Keywords:
Bone Metastases, Radiotherapy, Systemic Therapies, Pain Management, Personalized Treatment, Supportive CareAbstract
Introduction: Bone metastases (BM) are a major complication in patients with advanced cancer, resulting in pain, fractures, and other skeletal-related events (SREs) that greatly affect quality of life.
Objective: To provide an updated overview of the current management strategies for BM.
Methodology: This systematic review adhered to the PRISMA 2020 guidelines and was registered in PROSPERO (CRD42024586182). A comprehensive literature search was performed in July 2024 across PubMed, ScienceDirect, and Scopus, using terms related to BM and Boolean operators (OR, AND, and NOT). The search strategy was refined to only include studies published since January 2020. Randomized controlled trials (RCTs), clinical trials (CTs), and cohort and case-control studies published in English or Spanish assessing various management strategies for BM, such as surgery, radiotherapy, systemic therapies, and supportive care, and reporting data on the outcomes of interest were included. The Newcastle-Ottawa Scale was used for quality assessment.
Results: A total of 131 records were retrieved from the searches. After duplicate removal and title and abstract and full-text screening, 27 studies were included in the review: 13 RCTs, 7 CTs, 6 cohort studies, and 1 case-control study with an aggregate sample of 14 672 patients. Radiotherapy, particularly multifractionated regimens and stereotactic body radiotherapy, was shown to improve pain relief and bone stability. Systemic therapies, including immune checkpoint inhibitors and bone-targeted agents, demonstrated efficacy in reducing skeletal-related events. Emerging techniques such as percutaneous vertebroplasty combined with ablative methods demonstrate potential in minimizing complications and improving quality of life.
Conclusion: The management of BM continues to evolve, with personalized, multimodal approaches being essential for achieving optimal outcomes. Further research should focus on enhancing predictive models, exploring novel therapies, and integrating bone-targeted agents to reduce complications and improve both survival and quality of life in patients with bone metastases.
Downloads
References
Jayarangaiah A, Kemp AK, Theetha Kariyanna PT. Bone Metastasis. StatPearls. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: Available from: https://www.ncbi.nlm.nih.gov/books/NBK507911/. PMID: 29939688.
Huang JF, Shen J, Li X, Rengan R, Silvestris N, Wang M, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020;8(7):482. doi: 10.21037/atm.2020.03.55. PMID: 32395526; PMCID: PMC7210217.
Lan H, Wu B, Jin K, Chen Y. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers. Front Endocrinol (Lausanne). 2024;14:1260491. doi: 10.3389/fendo.2023.1260491. PMID: 38260135; PMCID: PMC10800370.
Riffel RM, Göbel A, Rachner TD. Bone Metastases: From Mechanisms to Treatment. Semin Oncol Nurs. 2022;38(2):151277. doi: 10.1016/j.soncn.2022.151277. PMID: 35474145.
Cerchiaro M, Angelini A, Pala E, Ruggieri P. Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature. Curr Oncol. 2025;32(4):226. doi: 10.3390/curroncol32040226. PMID: 40277781; PMCID: PMC12025461.
Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18(2):e1230. doi: 10.1002/cl2.1230. PMID: 36911350; PMCID: PMC8958186.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097. PMID: 19621072; PMCID: PMC2707599.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi: 10.1186/s13643-016-0384-4. PMID: 27919275; PMCID: PMC5139140.
Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa: Ottawa Hospital Research Institute; [cited 2025 Jun 4]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, et al. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. Eur J Cancer. 2023;182:66-76. doi: 10.1016/j.ejca.2022.12.028. PMID: 36746010.
Liakouli Z, Zygogianni A, Georgakopoulos I, Mystakidou K, Kouvaris J, Antypas C, et al. Osteolytic Bone Metastasis: Different Radiotherapy Fractionation Schedules Compared Clinically and Radiographically. Curr Oncol. 2024;31(6):3064-72. doi: 10.3390/curroncol31060233. PMID: 38920717; PMCID: PMC11202682.
Pielkenrood BJ, Gal R, Kasperts N, Verhoeff JJC, Bartels MMTJ, Seravalli E, et al. Quality of Life After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases. Int J Radiat Oncol Biol Phys. 2022;112(5):1203-15. doi: 10.1016/j.ijrobp.2021.12.163. PMID: 35017007.
Ge W, Liu X, Liu M, Zhuo W. Multisite Percutaneous Bone Augmentation for the Treatment of Acetabular Osteolytic Metastases Involving the Articular Surfaces: A Randomised Trial. Curr Med Imaging. 2023;20(1): e280323215024. doi: 10.2174/1573405620666230328083639. PMID: 37018524.
Hu TY, Zhang G, Ye H, An CL, Wang K, Xia L, et al. Pain Relief and Safety of Microwave Ablation Combined with Percutaneous Vertebroplasty for Vertebral Metastasis: A Pilot Study. J Neurol Surg A Cent Eur Neurosurg. 2023;84(6):513-20. doi: 10.1055/s-0042-1758121. PMID: 36495242.
Pielkenrood BJ, van der Velden JM, van der Linden YM, Bartels MMT, Kasperts N, Verhoeff JJC, et al. ain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort. Int J Radiat Oncol Biol Phys. 2021;110(2):358-67. doi: 10.1016/j.ijrobp.2020.11.060. PMID: 33333200.
van der Linden YM, Westhoff PG, Stellato RK, van Baardwijk A, de Vries K, Ong F, et al. Dexamethasone for the Prevention of a Pain Flare After Palliative Radiation Therapy for Painful Bone Metastases: The Multicenter Double-Blind Placebo-Controlled 3-Armed Randomized Dutch DEXA Study. Int J Radiat Oncol Biol Phys. 2020;108(3):546-53. doi: 10.1016/j.ijrobp.2020.05.007. PMID: 32446951.
Hettwer WH, Wu C, Horstmann PF, Jensen CL, Krarup-Hansen A, Petersen MM. Occlusive wound closure prevents prolonged wound discharge-A randomised controlled trial in patients undergoing tumour resection and endoprosthetic reconstruction of the proximal femur because of metastatic bone disease. Int Wound J. 2023;20(7):2802-10. doi: 10.1111/iwj.14159. PMID: 36946470; PMCID: PMC10410326.
Shi X, Cui Y, Pan Y, Wang B, Lei M. A Nomogram to Predict Intra-Spinal Canal Cement Leakage Among Elderly Patients with Spine Metastases: An Internal-Validated Model. Clin Interv Aging. 2021;16:1735-46. doi: 10.2147/CIA.S330783. PMID: 34616147; PMCID: PMC8487801.
Shi X, Cui Y, Pan Y, Wang B, Lei M. Prediction of early vascular cement leakage following percutaneous vertebroplasty in spine metastases: the Peking University First Hospital Score (PUFHS). BMC Cancer. 2021;21(1):764. doi: 10.1186/s12885-021-08503-2. PMID: 34215238; PMCID: PMC8254210.
Gillespie EF, Santos PMG, Curry M, Salz T, Chakraborty N, Caron M, et al. Implementation Strategies to Promote Short-Course Radiation for Bone Metastases. JAMA Netw Open. 2024;7(5):e2411717. doi: 10.1001/jamanetworkopen.2024.11717. PMID: 38787561; PMCID: PMC11127116.
Mercier C, Claessens M, Buys MSc A, Gryshkevych S, Billiet C, Joye I, et al. Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial. Int J Radiat Oncol Biol Phys. 2021;109(5):1195-205. doi: 10.1016/j.ijrobp.2020.11.066. PMID: 33307151.
Deandreis D, Maillard A, Zerdoud S, Bournaud C, Vija L, Sajous C, et al. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2021;48(10):3238-49. doi: 10.1007/s00259-021-05229-y. PMID: 33619600; PMCID: PMC8426251.
van de Ven S, van den Bongard D, Pielkenrood B, Kasperts N, Eppinga W, Peters M, et al. Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort. Int J Radiat Oncol Biol Phys. 2020;107(1):39-47. doi: 10.1016/j.ijrobp.2019.12.041. PMID: 32007565.
Huele EH, van der Velden JM, Kasperts N, Eppinga WSC, Grutters JPC, Suelmann BBM, et al. Stereotactic Body Radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design. Trials. 2023;24(1):307. doi: 10.1186/s13063-023-07315-y. PMID: 37143158; PMCID: PMC10157966.
Xu L, Huang X, Lou Y, Xie W, He J, Yang Z, et al. Prognostic analysis of percutaneous vertebroplasty (PVP) combined with 125I implantation on lumbosacral vertebral osteoblastic metastases. World J Surg Oncol. 2023;21(1):391. doi: 10.1186/s12957-023-03268-3. PMID: 38124135; PMCID: PMC10731753.
Ghadjar P, Stritter W, von Mackensen I, Mehrhof F, Foucré C, Ehrhardt VH, et al. External application of liver compresses to reduce fatigue in patients with metastatic cancer undergoing radiation therapy, a randomized clinical trial. Radiat Oncol. 2021;16(1):76. doi: 10.1186/s13014-021-01757-x. PMID: 33874968; PMCID: PMC8054395.
Napoli A, De Maio A, Alfieri G, Gasperini C, Scipione R, Campanacci L, et al. Focused Ultrasound and External Beam Radiation Therapy for Painful Bone Metastases: A Phase II Clinical Trial. Radiology. 2023;307(2):e211857. doi: 10.1148/radiol.211857. PMID: 36594834.
Geerling JI, van der Linden YM, Raijmakers NJH, Vermeulen KM, Mul VEM, de Nijs EJM, et al. Randomized controlled study of pain education in patients receiving radiotherapy for painful bone metastases. Radiother Oncol. 2023;185:109687. doi: 10.1016/j.radonc.2023.109687. Epub 2023 May 9. PMID: 37169300.
Gazendam AM, Ghert M, Gundle KR, Hayden JB, Doung Y-C; PARITY Investigators. Opioid Use in Surgical Management in Musculoskeletal Oncology. J Bone Joint Surg Am. 2023;105(Suppl 1):10-4. doi: 10.2106/JBJS.22.00887. PMID: 37466574.
Fallon M, Sopata M, Dragon E, Brown MT, Viktrup L, West CR, et al. A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis. Oncologist. 2023;28(12):e1268-78. doi: 10.1093/oncolo/oyad188. PMID: 37343145; PMCID: PMC10712717.
Sakr A, Hashem WB, Ebrahim N, Mashhour KN. Randomized Pilot Study of 20 Gy in 5 Fractions Versus 27 Gy in 3 Fractions Radiotherapy for Treating Painful Bone Metastases: A Single Institution Experience. Asian Pac J Cancer Prev. 2020;21(6):1807-11. doi: 10.31557/APJCP.2020.21.6.1807. PMID: 32592381; PMCID: PMC7568878.
Lou Y, Chen Y, Yuan Y, Wang R, Shan H. Study on the Correlation between Pain and Cytokine Expression in the Peripheral Blood of Patients with Bone Metastasis of Malignant Cancer Treated Using External Radiation Therapy. Pain Res Manag. 2022;2022:1119014. doi: 10.1155/2022/1119014. PMID: 35845981; PMCID: PMC9287001.
Hardtstock F, Kocaata Z, Wilke T, Dittmar A, Ghiani M, Belozeroff V, et al. Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events. Eur J Health Econ. 2021;22(2):243-54. doi: 10.1007/s10198-020-01247-z. PMID: 33459901; PMCID: PMC7881971.
Zeng KL, Abugarib A, Soliman H, Myrehaug S, Husain ZA, Detsky J, et al. Dose-Escalated 2-Fraction Spine Stereotactic Body Radiation Therapy: 28 Gy Versus 24 Gy in 2 Daily Fractions. Int J Radiat Oncol Biol Phys. 2023;115(3):686-95. doi: 10.1016/j.ijrobp.2022.09.076. PMID: 36309076.
Muller DA, Wages NA, Wilson DD, Dutta SW, Alonso CE, Handsfield LL, et al. STAT RAD: Prospective Dose Escalation Clinical Trial of Single Fraction Scan-Plan-QA-Treat Stereotactic Body Radiation Therapy for Painful Osseous Metastases. Pract Radiat Oncol. 2020;10(6):e444-51. doi: 10.1016/j.prro.2020.03.008. PMID: 32289551.
Harada H, Shikama N, Wada H, Uchida N, Nozaki M, Hayakawa K, et al. A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma. Jpn J Clin Oncol. 2021;51(1):100-5. doi: 10.1093/jjco/hyaa158. PMID: 32869095.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Author(s).
This work is licensed under a Creative Commons Attribution 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
